Company intelligence / Profile preview

TaiGen Biotechnology Co., Ltd.

Ownership: Private
Employees: ~70
Development stage: Other

Overview

TaiGen has successfully developed and commercialized Taigexyn® (nemonoxacin) in oral and intravenous formulations for community-acquired pneumonia in Taiwan and mainland China. Their influenza drug TG-1000 completed Phase III trials and filed NDA in mainland China in 2024[4]. They also have other products in various clinical stages.

Therapeutic areas: OncologyHematologyCardiovascularInfectious Diseases
Modalities: Small molecules
Industry: Biotech

Drug pipeline

3 assets

nemonoxacin

2 more assets in the full pipeline.

Partnerships

Procter & Gamble PharmaceuticalsGPCR (South Korea)R-Pharm (Russian Federation and Commonwealth of Independent States)Productos Científicos (Latin America)Holding Distribution (Taiwan)Zhejiang Medicine Co. (China)BioXell SpAArena Pharmaceuticals

Beyond the preview

Go deeper on TaiGen Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TaiGen Biotechnology Co., Ltd..